Contributions
Abstract: EP1651
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: The interferon beta-1b ( IFNB-1b) was approved 25 year ago for the treatment of relapsing remitting MS. Researchers have shown that 13-30% of patients discontinued therapy.
Aims: This study aims to highlight adherence to long-term treatment with IFNB-1b.
Objectives: The primary outcome of this study was to assess the degree of adherence and the reasons for discontinuation of INFB-1b treatment, during 17 year follow- up.
Methods: In our observational retrospective study, we included a group of 88 relapsing remitting multiple sclerosis (RRMS) patients and 12 secondary progresive multiple sclerosis (SPMS) patients. They started IFNB-1b treatment subcutaneously at a dose of 250 µg every other day. The inclusion period took place between October 2000 and March 2001, while the follow-up ended on March 2018. The including criteria for treatment were: age between 18-56 years and EDSS score under 5,0. Our patients underwent clinical evaluation every six months, focused on the number of relapses, EDSS score, and adverse events.
Results: Mean follow up was 11 years. During this period, 62% discontinued treatment. Patients desire (lack of efficacy) was the main reason for stopping the treatment (27%). Other factors included: moving to another place (10%), adverse events (7%), reaching the EDSS score ≥ 8 (6%), reconsidering the diagnosis (5%), pregnancy (3%) and other reasons (4%).
Conclusion: Only 38% MS patients were persistent to INFB-1b treatment during 17 year exposure. Lack of efficacy (patient's opinion) was the main reasons for stopping treatment, despite a good safety profile.
Disclosure: Sirbu CA has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from, Bayer, Novartis, Merck, Shering, Ever and Teva
Caloianu I has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from Bayer, Biogen-Idec, Novartis, Shering, Janssen and Teva
Florina Stoian has nothing to disclose
Mihaela Mirela Micu has nothing to disclose
Plesa FC has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from Aventis, Bayer, Biogen-Idec, Novartis, Sanofi-Zentiva, Serono, Shering and Teva
Abstract: EP1651
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Introduction: The interferon beta-1b ( IFNB-1b) was approved 25 year ago for the treatment of relapsing remitting MS. Researchers have shown that 13-30% of patients discontinued therapy.
Aims: This study aims to highlight adherence to long-term treatment with IFNB-1b.
Objectives: The primary outcome of this study was to assess the degree of adherence and the reasons for discontinuation of INFB-1b treatment, during 17 year follow- up.
Methods: In our observational retrospective study, we included a group of 88 relapsing remitting multiple sclerosis (RRMS) patients and 12 secondary progresive multiple sclerosis (SPMS) patients. They started IFNB-1b treatment subcutaneously at a dose of 250 µg every other day. The inclusion period took place between October 2000 and March 2001, while the follow-up ended on March 2018. The including criteria for treatment were: age between 18-56 years and EDSS score under 5,0. Our patients underwent clinical evaluation every six months, focused on the number of relapses, EDSS score, and adverse events.
Results: Mean follow up was 11 years. During this period, 62% discontinued treatment. Patients desire (lack of efficacy) was the main reason for stopping the treatment (27%). Other factors included: moving to another place (10%), adverse events (7%), reaching the EDSS score ≥ 8 (6%), reconsidering the diagnosis (5%), pregnancy (3%) and other reasons (4%).
Conclusion: Only 38% MS patients were persistent to INFB-1b treatment during 17 year exposure. Lack of efficacy (patient's opinion) was the main reasons for stopping treatment, despite a good safety profile.
Disclosure: Sirbu CA has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from, Bayer, Novartis, Merck, Shering, Ever and Teva
Caloianu I has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from Bayer, Biogen-Idec, Novartis, Shering, Janssen and Teva
Florina Stoian has nothing to disclose
Mihaela Mirela Micu has nothing to disclose
Plesa FC has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from Aventis, Bayer, Biogen-Idec, Novartis, Sanofi-Zentiva, Serono, Shering and Teva